Omeros touts positive trial for eye surgery therapy; Pozen shares jump on licensing pact;

@FierceBiotech: Labopharm slashes staff, pushes strategic review. News | Follow @FierceBiotech

@JohnCFierce: Looks like Peptimmune is heading off into the sunset. Article | Follow @JohnCFierce

> Seattle-based Omeros says that its experimental therapy for patients undergoing cataract surgery proved promising in a mid-stage study, paving the way to a pivotal Phase III trial. Story

> Shares of Pozen jumped five percent this morning after it announced that it had licensed some Latin American rights to its migraine drug MT400 to a unit of J&J for an undisclosed upfront fee and milestones. Report

> Quintiles says that it has shelved financing plans outlined earlier in the month. Story

> After seeing its share price shoot up Prana Biotechnology in Australia is raising a little more than $6 million through a private placement. Prana release

> RTU and Sucampo Manufacturing and Research AG inked a licensing agreement to develop, manufacture, and commercialize Unoprostone (Rescula) in regions excluding Japan, Taiwan, Republic of Korea, the People's Republic of China and North America. Report

Pharma News

> With Sanofi-Merck deal off, look for animal health M&A. Report

> Payers may balk at Makena pricing, KV says. Story

> Bill would require Medicare to pay for off-label meds. Article

> SC jury finds J&J letter violated consumer laws. Story

> Pfizer chiefs new and old get big bumps in pay. News

> Pfizer in talks with feds on Protonix rebate charges. Report

Drug Delivery News

> Tekmira sues RNAi drug-delivery partner Alnylam. Report 

> Puzzle solved to deliver RNA drugs into brain. News

> MRI guides cancer drug directly to liver. Story 

> Startup with "spidersilk" for drug delivery raises $7M. Item 

> OncoSec, cancer drug delivery firm, taking form. Article 

> More cancer-killing gold found in gold nanoparticles? Story

Medical Device News

> ACT study aims to demonstrate safety, efficacy of TEMPASURE catheter. News

> Ex-Exactech rep to pay $56K for role in kickback scheme. Story

> Terumo unit enters consent decree, gives up $35M in profits. Article

> St. Jude shares up on JP Morgan analyst note. Report 

> ReGen says it's fed up with FDA's 'agenda,' refuses hearing. News

> Nordion to evaluate TheraSphere in PhIII. Story

> Core Essence raises $11.5M in Series B funding. Article

And Finally... Investigators at Tufts Medical Center say that occasional sex significantly raises the risk of a heart attack. Story

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.